Nucleix Demonstrates Potential of its PCR EpiCheck® Ass

SAN DIEGO & REHOVOT, Israel, April 04, 2024--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes. The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10

Related Keywords

Israel , United States , Texas , San Diego , California , American , Jake Robison , Mathias Ehrich , University Of Texas Md Anderson Cancer Center , Nucleix Ltd , American Association For Cancer Research , American Association , Cancer Research , Annual Meeting , Cancer Center , Epigenetic Targets , Poster Number , The Company , Small Cell Lung Cancer , Cancer Treatment , Racr , Clc , Pcr Assay , Liquid Biopsy , Poster Presentation , Na Methylation ,